Results 101 to 110 of about 45,492 (265)

SGLT2 inhibitors for the prevention and treatment of heart failure: A scientific statement of the HFA and the HFAI

ESC Heart Failure, EarlyView.
Abstract In the 2021 European Society of Cardiology (ESC) heart failure (HF) guidelines, sodium–glucose cotransporter 2 (SGLT2) inhibitors were recommended for the prevention of HF in patients with type 2 diabetes mellitus (T2DM) and for the treatment of HF with reduced ejection fraction (HFrEF).
Marco Metra, Daniela Tomasoni, Marianna Adamo, Offer Amir, Stefan D. Anker, Antoni Bayes‐Genis, Michael Boehm, Javed Butler, Ovidiu Chioncel, Gerasimos Filippatos, Finn Gustafsson, Ewa A. Jankowska, Juan Carlos Kaski, Brenda Moura, Mark C. Petrie, Piotr Ponikowski, Amina Rakisheva, Arsen Ristic, Francois Roubille, Gianluigi Savarese, Petar Seferovic, Peter van der Meer, Maurizio Volterrani, Andrew J. Coats, Vijay K. Chopra, Giuseppe Rosano   +25 more
wiley   +1 more source

In Primary Aldosteronism, Mineralocorticoids Influence Exosomal Sodium-Chloride Cotransporter Abundance

, 2016
Martin Wolley, Aihua Wu, Shengxin Xu, Richard D. Gordon, Robert A. Fenton, Michael Stowasser   +5 more
openalex   +1 more source

Geographic region variation in patient characteristics, clinical outcomes and treatment of HFrEF in the VICTORIA trial

ESC Heart Failure, EarlyView.
Central Illustration caption: This analysis of vericiguat's treatment effect revealed no inter‐geographic region heterogeneity for the primary composite endpoint (time to HF‐related hospitalization or cardiovascular (CV) death or its components) (Left Panel).
Cynthia M. Westerhout, Wendimagegn Alemayehu, Alain Cohen‐Solal, Carolyn S. P. Lam, Justin A. Ezekowitz, Stefano Corda, Ciaran J. McMullan, Christopher M. O'Connor, Paul W. Armstrong, for the VICTORIA Study Group   +9 more
wiley   +1 more source

A COMPARATIVE ASSESSMENT OF THE EFFECT OF MINERALOCORTICOID RECEPTOR ANTAGONISTS ON CHANGES IN GALECTIN-3 AND MMP-1 FIBROSIS MARKERS IN PATIENTS WITH CHRONIC CARDIAC FAILURE COMBINED WITH TYPE 2 DIABETES MELLITUS WITH MANIFESTATIONS OF MYOCARDIUM DYSSYNCHRONY

Journal of V. N. Karazin Kharkiv National University: Series Medicine, 2016
A comparative assessment of the effect of mineralocorticoid receptor antagonists on changes in galectin 3 and matrix metalloproteinase 1 fibrosis markers has been carried out on 106 examinations (average age (69 + 10.37) years) with type 2 DM and CCF of ...
T. A. Rudenko
doaj  

Percutaneous endocardial alginate–hydrogel injection in the treatment of heart failure: First‐in‐human study

ESC Heart Failure, EarlyView.
Using EndoWings™ and XDROP™, we developed a percutaneous minimally invasive technique for sequential circumferential alginate hydrogel injection into LV free mid‐wall. This human study assessed its safety/feasibility in HFrEF patients, with personalised biomechanical models.
Bo Wang, Shuo Wang, Chao Gao, D. Scott Lim, Rutao Wang, Xin Meng, Ying Liu, Cun‐jun Zhu, Yoshinobu Onuma, Yunbing Wang, Patrick W.J.C. Serruys, Runlin Gao, Randall J. Lee, Ling Tao   +13 more
wiley   +1 more source

Evidence for Aldosterone Antagonism in Heart Failure

Cardiac Failure Review
Activation of the renin–angiotensin–aldosterone system is the ultimate pathophysiological hallmark in heart failure. Though aldosterone primarily appears to regulate electrolyte homeostasis by acting on distal nephrons in the kidneys, its effects are far-
Rishi Sethi, Pravesh Vishwakarma, Akshyaya Pradhan   +2 more
doaj   +1 more source

Nurse‐coordinated multidisciplinary comprehensive heart failure management programme: A propensity‐matched trial

ESC Heart Failure, EarlyView.
Abstract Aims Despite therapeutic advancements, the prognosis of heart failure (HF) remains poor, with high rates of mortality and readmission, particularly following a HF exacerbation. This study aimed to evaluate the effects of a nurse‐coordinated multidisciplinary comprehensive HF management programme on HF patients.
Cecilia Miu‐Ching Chan, Polly Wai‐Chi Li, Derek Pok‐Him Lee, Esmond Yan‐Hang Fong, Ivy Sin‐Yee Ng, Samantha Ki‐Man Chiu, Clara Woon‐Shan Fok, Frederick Kin‐Wa Li, Shirley Ka‐Wai Lee, Karen K. Y. Ho, Wilson Y. S. Leung, Cathy Cheuk‐Sum Chan, Cindy Yiu‐Ning Tsang, Michael Kang‐Yin Lee   +13 more
wiley   +1 more source

Soluble urokinase plasminogen activator receptor and outcomes in HFpEF: A TOPCAT ancillary study

ESC Heart Failure, EarlyView.
Abstract Aims Inflammation is postulated to be a key pathogenic mechanism in heart failure with preserved ejection fraction (HFpEF). Soluble urokinase plasminogen activator receptor (suPAR), a regulator of innate immune activity, is associated with incident heart failure; however, its role in HFpEF remains unclear.
Christina G. Hutten, Annika Tekumulla, Anis Ismail, Alexi Vasbinder, Theresa Farhat, Pennelope Kunkle, Sascha N. Goonewardena, Ahmed Abdel‐Latif, Bertram Pitt, Salim S. Hayek   +9 more
wiley   +1 more source

Finerenone in diabetic chronic kidney disease—Real‐world insights including patients with HFpEF or HFmrEF

ESC Heart Failure, EarlyView.
Abstract Purpose Finerenone, a highly selective non‐steroidal mineralocorticoid receptor antagonist, was approved for the treatment of patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (diabetic kidney disease, DKD). Finerenone reduced the composite endpoint of heart failure events and cardiovascular death in patients with heart ...
Kristian Hellenkamp, Sophia Kaebe, Miroslava Valentova, Stephan von Haehling, Fani Delistefani, Katja Gollisch, Dirk Raddatz, Ann‐Kathrin Schäfer, Michael J. Koziolek, Manuel Wallbach   +9 more
wiley   +1 more source

Drug–Drug Interactions of the Nonsteroidal Mineralocorticoid Receptor Antagonist Apararenone With Midazolam, Warfarin, and Digoxin: A Phase 1 Studies in Healthy Volunteers

, 2020
Tadakatsu Nakamura, H. Shimizu, Atsuhiro Kawaguchi   +2 more
openalex   +1 more source